טוען...
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multi-continent clinical trial
Acyclovir suppressive therapy (400 mg twice daily) reduces herpes simplex virus type 2 (HSV-2) associated genital ulcer disease (GUD) and lesional HSV shedding. In an international trial of acyclovir for HSV-2 suppression to prevent HIV acquisition (HPTN 039), acyclovir had a smaller effect on the f...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2856478/ https://ncbi.nlm.nih.gov/pubmed/20214474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1086/651381 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|